Open an account

Erasca

ERAS · NASDAQ

$14.62+$1.00 (+7.34%)TodayMarket closed ·
Prev close $13.62

About ERAS

Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Employees
103
Headquarters
San Diego, California
Listed
Jul 15, 2021
Sector
Health Care
Industry
Biotechnology
Website
erasca.com

ERAS key statistics

Market cap
5.11B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.39M
Volume
4.22M
Open price
$13.40
High today
$14.97
Low today
$13.10
52 Week high
$24.28
52 Week low
$2.11

Erasca (ERAS) at a glance

Erasca (ERAS) last traded at $14.62, with a market cap of 5.11B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $13.10 and $14.97. The current price is 11.6% above the day's low and 2.3% below its high.

Volume so far is 4.22M shares, below the average of 5.39M shares a day.

Over the past year Erasca has ranged from $2.11 to $24.28, and now sits 56% of the way up that range.

Erasca met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.14 per share against an estimate of -$0.1039.

The average analyst price target is $23.12, 58.1% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

83%of 12 analyst ratings say Buy
  • Buy83.3%
  • Hold16.7%
  • Sell0.0%
Price target · 12 analystsAvg $23.12
Low
$20.20
Now
$14.62
High
$31.50

ERAS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 17.8% on average.

  1. Q3 FY24: reported -$0.11 per share against an estimate of -$0.17
  2. Q4 FY24: reported -$0.11 per share against an estimate of -$0.1265
  3. Q1 FY25: reported -$0.11 per share against an estimate of -$0.1285
  4. Q2 FY25: reported -$0.12 per share against an estimate of -$0.1122
  5. Q3 FY25: reported -$0.11 per share against an estimate of -$0.1054
  6. Q4 FY25: reported -$0.10 per share against an estimate of -$0.1091
  7. Q1 FY26: reported -$0.60 per share against an estimate of -$0.2131
  8. Q2 FY26: reported -$0.14 per share against an estimate of -$0.1039

ERAS news

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

  • Press releaseGlobe Newswire

    Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); Erasca, Inc. (NASDAQ: ERAS); and Hub Group, Inc. (NASDAQ: HUBG): Grabar Law Office is Investigating Claims on Your Behalf

  • Press releaseGlobe Newswire

    Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf

  • Press releaseGlobe Newswire

    Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Erasca, Inc. (ERAS)

  • Press releaseBusiness Wire

    CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

  • Press releasePRNewswire

    Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline

  • Press releasePRNewswire

    Erasca, Inc. Investor Alert: Contact SBS by August 10, 2026 for Opportunity to Lead Securities Fraud Lawsuit

  • Press releasePRNewswire

    Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline

Similar companies

Companies in the same industry as Erasca

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.